13 Investigates
US$ 25.28
drugs glp-1 America's Poison Centers GLP-1 medications get at the
Description
Neuropsychopharmacology 43, 20002008
Key Takeaways: Rapid adoption is driving better access, but irrational, unsupervised use is raising red flags
Through a reduction in extracellular glutamate and an increase in pro-survival signaling, Hernndez et al
Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al
the total size of the obesity therapeutics market could swell to $100B by 2026
